Evidence map›Paper›PMID 17659190›Full record

ReviewNeurologic clinics2007

Rapidly progressive dementia.

Michael D Geschwind, Aissa Haman, Bruce L Miller

Abstract readReview
In one paragraph

Review in Neurologic clinics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Autoimmune Encephalitis Resembling Dementia Syndromes.Neurology(R) neuroimmunology & neuroinflammation · 2021
    Observational
  15. Selective vulnerability to atrophy in sporadic Creutzfeldt-Jakob disease.Annals of clinical and translational neurology · 2021
    Article
  16. Article
  17. Baseline neuropsychological profiles in prion disease predict survival time.Annals of clinical and translational neurology · 2020
    Article
  18. Acute presentation of dementia with Lewy bodies.Clinical medicine (London, England) · 2019
    Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael D GeschwindDepartment of Neurology, Memory & Aging Center, University of California, San Francisco Medical Center, San Francisco, CA 94117, USA. mgeschwind@memory.ucsf.edu
Aissa Haman
Bruce L Miller

Funding

Predicting progression of human prion diseaseR01AG031189 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2008 to 2017
$5.7M
NIA NIH HHS R01 AG031189
6 · The paper itself

Abstract

Rapidly progressive dementias (RPDs) are neurologic conditions that develop subacutely over weeks to months or, rarely, acutely over days. In contrast to most dementing conditions that take years to progress to death, RPD quickly can be fatal. It is critical to evaluate patients who have RPD without delay, usually in a hospital setting, as they may have a treatable condition. This review discusses a differential diagnostic approach to RPD, emphasizing neurodegenerative, toxic and metabolic, infectious, autoimmune, neoplastic, and other conditions to consider.

Indexed as

AlgorithmsBrain DiseasesCreutzfeldt-Jakob SyndromeDiagnosis, DifferentialHumansPractice Guidelines as Topic

Identifiers

PMID17659190
PMCPMC2706263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.